使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
各位女士、先生,早安,歡迎參加百特國際(Baxter International)2018 年第二季財報電話會議。(接線員指示)提醒各位,本次電話會議由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請立即掛線。
I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.
現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,您可以開始了。
Clare Trachtman - VP of IR
Clare Trachtman - VP of IR
Thanks Candace. Good morning, and welcome to our second quarter 2018 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.
謝謝 Candace。各位早安,歡迎參加我們 2018 年第二季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。
On the call this morning, we will be discussing Baxter's second quarter 2018 financial results along with our updated financial outlook for 2018. A supplemental presentation to complement this morning's discussion can be accessed on our website. This presentation, along with the related non-GAAP reconciliations, can be accessed on Baxter's external website in the Investors section under Events and News.
今天早上的電話會議中,我們將討論百特 2018 年第二季財務結果,以及我們更新後的 2018 年財務展望。可於我們的網站取得補充簡報,以配合今天早上的討論。該簡報以及相關的非 GAAP 調節表,可在百特對外網站「投資人」專區下的「活動與新聞」中取得。
With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters, contains forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.
接下來,我先以預先準備的發言提醒各位:本簡報(包括關於我們財務展望、新產品開發、業務開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。關於可能導致實際結果與預期有重大差異的因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得更多細節。
In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性的營運表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含在我們今早發布的財報新聞稿中,並可於我們網站取得。
Now I'd like to turn the call over to Joe. Joe?
現在我想把電話交給 Joe。Joe?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Thank you, Clare, and good morning to everyone joining us. I'm going to share a few comments on our second quarter performance, then Jay will walk through the financials and guidance in more detail. And we will close, as always, by taking your questions.
謝謝你,Clare,也向所有加入我們的各位道早安。我將先分享幾點關於我們第二季表現的看法,接著 Jay 會更詳細說明財務數字與財測指引。最後,我們一如既往會進入問答時間。
I would like to start by saying how energizing it was meeting with so many of you face-to-face at our investor conference. Thanks also to those of you who attended online or watched the replay. Our team was excited to share the next chapter in Baxter's story, our progress to date and more importantly, our opportunities and outlook ahead.
我想先說,在投資人會議上與各位面對面交流令人振奮。也感謝透過線上參與或觀看重播的各位。我們的團隊很高興能分享百特故事的下一篇章、迄今的進展,更重要的是,未來的機會與展望。
We set a clear path to deliver approximately 5% compounded annual growth through 2023. We will accomplish this objective by building on the strength of our base business and accelerating innovation. As we shared at the conference, we plan to introduce new therapies and products that I expect to contribute approximately $1.7 billion of sales by 2023.
我們已設定清晰路徑,目標是在 2023 年前實現約 5% 的年複合成長。我們將透過鞏固核心業務的優勢並加速創新來達成此目標。如同我們在會議上分享的,我們計畫推出新的療法與產品,我預期到 2023 年可貢獻約 17 億美元的銷售額。
At the same time, we remained relentless focus on re-enhancing operational efficiency to deliver increased value to shareholders. And we will augment this performance with business development, expanding into new adjacencies and unlocking new markets to drive incremental value for all the stakeholders.
同時,我們也持續以不懈的專注重新提升營運效率,為股東創造更高價值。我們也將透過業務開發來強化這項表現,拓展至新的相鄰領域並開拓新市場,為所有利害關係人帶來增量價值。
Now turning to the quarter, second quarter 2018 sales were up 9% on a reported basis, 5% on a constant currency basis and 4% operationally. Second quarter operational sales adjust for the impact of foreign exchange, generic competition for cyclophosphamide in the U.S., the Claris acquisition and our acquisition of 2 surgical products from Mallinckrodt. The strength in the quarter was driven by double-digit growth in our pharmaceuticals business, which benefited from increased sales of injectable pharmaceuticals in the U.S., and the addition of Claris, which contributed $33 million of sales in the quarter.
回到本季,2018 年第二季銷售額以申報基礎計成長 9%,以固定匯率基礎計成長 5%,以營運基礎計成長 4%。第二季營運銷售額已調整外匯影響、美國環磷醯胺(cyclophosphamide)的學名藥競爭、Claris 併購案,以及我們自 Mallinckrodt 收購兩項外科產品的影響。本季的強勁表現主要來自我們製藥業務的兩位數成長,受惠於美國注射用藥銷售增加,以及 Claris 的併入;Claris 本季貢獻 3,300 萬美元銷售額。
We also experienced double-digit growth in our advanced surgery business, driven by solid international performance and the addition of RECOTHROM and PREVELEAK, which contributed $17 million of sales during the quarter. Our acute therapies business continued to deliver double-digit growth for the company, performance in the quarter was driven by 20% growth in the U.S., where we remain focused on increasing CRRT adoption and securing new customers.
我們的先進外科業務亦呈現兩位數成長,主要由穩健的國際表現及 RECOTHROM 與 PREVELEAK 的併入所帶動,兩者於本季合計貢獻 1,700 萬美元銷售額。我們的急性療法業務持續為公司帶來兩位數成長;本季表現由美國市場 20% 的成長所驅動,我們仍專注於提升 CRRT 的採用並爭取新客戶。
Increased demand for our contract manufacturing services as well as solid growth in our renal care business also contributed to growth in the quarter. This momentum helped to offset declines in medication delivery and clinical nutrition. Digging into this specific performance a bit further, with respect to large volume parenterals or LVPs, we continued to gain new customers in U.S. following the reallocation of volume from Mexico to the U.S. But the update in timing of these additions has been somewhat slower than anticipated. We are confident in our ability to continue to gain additional new customers in the second half of the year.
對我們委託製造服務需求的增加,以及腎臟照護業務的穩健成長,也共同推升本季成長。這股動能有助於抵銷藥物輸注(medication delivery)與臨床營養的下滑。進一步說明此項表現:就大容量注射液(LVPs)而言,在將產能自墨西哥重新分配至美國之後,我們持續在美國取得新客戶,但這些新增客戶導入的時程更新後,進度較原先預期略慢。我們對於在下半年持續取得更多新客戶的能力仍具信心。
Performance in medication delivery was also impacted by the lower sales of small volume parenterals or SVPs in the quarter. While production volumes continue to improve, supply of these products has remained tight. As such, we were unable to restore our distribution partners back to pre-hurricane supply levels for all SVP product codes during the quarter. Given current production levels, we expect this supply dynamic for SVPs to improve in the coming weeks.
藥物輸注業務的表現亦受到本季小容量注射液(SVPs)銷售較低的影響。雖然產量持續改善,但這些產品的供應仍然吃緊。因此,本季我們無法讓所有 SVP 產品代碼的供應,全面恢復至颶風前的水準以供應我們的經銷夥伴。以目前的生產水準來看,我們預期 SVP 的供應狀況將在未來幾週改善。
For our nutritional therapies, we have experienced a delay in customers returning to their historical purchasing patterns that preceded Hurricane Maria. Our marketing teams are working closely with our customers to reinforce availability of products and recapture those sales.
在營養療法方面,我們觀察到客戶回到瑪麗亞颶風(Hurricane Maria)之前的歷史採購模式有所延遲。我們的行銷團隊正與客戶密切合作,強化產品供應可得性的訊息並重新爭取這些銷售。
Overall, our sales performance conveys the strategic benefits of our diversified portfolio, helping ensure that temporary headwinds in certain areas are counterbalanced by performance, company-wide. On the bottom line, adjusted earnings per share was $0.77, a 22% year-over-year increase. This reflects the impact of our top line growth as well as the ongoing impact of our business transformation initiatives.
整體而言,我們的銷售表現展現了多元化產品組合的策略效益,有助於確保某些領域的短期逆風能由公司整體的表現所平衡。在獲利方面,調整後每股盈餘為 0.77 美元,年增 22%。這反映了營收成長的影響,以及我們業務轉型計畫持續帶來的效益。
At the Investor Conference, we emphasized that product innovation is central to our go-forward growth strategy. Some key recent highlights reflect this commitment: expansion of the company's medication delivery portfolio with 2 new innovative drug infusion pumps, FDA and Health Canada approvals of the Spectrum IQ infusion system, with Dose IQ Safety Software, our latest smart-pump platform features bidirectional EMR integration and other enhancements to help reduce programming errors and enhance patient safety; CE marking for the Evo IQ Infusion System in the United Kingdom and Ireland, representing the first in a series of planned regulatory submissions internationally.
在投資人會議上,我們強調產品創新是我們未來成長策略的核心。近期幾項重點亮點反映了這項承諾:以兩款創新藥物輸注幫浦擴充公司藥物輸注產品組合;Spectrum IQ 輸注系統(搭載 Dose IQ 安全軟體)取得美國 FDA 與加拿大衛生部(Health Canada)核准;我們最新的智慧幫浦平台具備雙向 EMR 整合及其他強化功能,以協助降低程式設定錯誤並提升病患安全;Evo IQ 輸注系統在英國與愛爾蘭取得 CE 認證,這是我們規劃於國際間進行一系列法規送件的第一步。
In Canada, we advanced the launch of a new indication for our oXiris set. oXiris is the first blood purification set that can be used in continuous renal replacement therapy, CRRT, and sepsis management protocols, and it is now approved in more than 30 countries. And we introduced key program updates for our SHARESOURCE remote patient management platform to support greater accessibility and efficiencies in remotely viewing PD patient data.
在加拿大,我們推進 oXiris 濾器組(set)新適應症的上市。oXiris 是首款可用於連續性腎臟替代治療(CRRT)與敗血症管理流程的血液淨化濾器組,目前已在超過 30 個國家獲准。此外,我們也發布 SHARESOURCE 遠端病患管理平台的重要方案更新,以支援更高的可近性與效率,讓使用者能遠端檢視 PD 病患資料。
Another theme at the Investor Conference was addressing our untapped potential in Japan. In Q2, we continued the successful rollout of our KAGUYA APD system with embedded SHARESOURCE technology, which targets Japan's unique market needs. Plus, we have recently initiated the launch of our PRISMAFLEX system, which positions Baxter in Japan as the only comprehensive one-stop partner in the acute care space.
投資人會議的另一個主題,是釋放我們在日本尚未充分發揮的潛力。在第二季,我們持續成功推廣內建 SHARESOURCE 技術、並鎖定日本獨特市場需求的 KAGUYA APD 系統。此外,我們近期也已啟動 PRISMAFLEX 系統的上市,使百特在日本的急性照護領域成為唯一提供完整一站式解決方案的合作夥伴。
Before closing, I would quickly share a few words about Claris. As you know, last week, the FDA released a warning letter regarding our legacy Claris injectables facility in Ahmedabad, India. The FDA initiated a site inspection at the time of the closing of our Claris acquisition, which took place 1 year ago this week. We have already taken many corrective actions in response to the FDA's original Form 483 observations. We are continuing to undertake actions and facility improvements as we integrate Ahmedabad into our Baxter quality systems. The Claris deal is an important platform for the expansion of our pharmaceuticals portfolio and pipeline.
在結束之前,我想簡短分享幾點關於 Claris 的情況。如各位所知,上週 FDA 就我們位於印度阿默達巴德(Ahmedabad)的既有 Claris 注射劑廠發布了一封警告信。FDA 在我們完成 Claris 收購交割之際啟動了現場稽查;該交割就在本週滿 1 週年。針對 FDA 原先 Form 483 的觀察事項,我們已採取多項矯正措施。在將阿默達巴德整合進 Baxter 的品質系統之際,我們仍持續推動相關行動與廠房改善。Claris 交易是我們擴展製藥產品組合與研發管線的重要平台。
Financial results over the past year have tightly aligned with our expectations. And as indicated in our 8-K, we don't currently expect for the warning letter to have any material impact on our long-range financial outlook issued this past May. We are continuing to invest in Ahmedabad to expand local capabilities, technologies and expertise. We have made solid progress, and we'll continue working with FDA to ensure all outstanding observations are resolved as quickly and comprehensively as possible.
過去一年的財務結果與我們的預期高度一致。且如我們在 8-K 中所述,我們目前不預期該警告信會對我們今年 5 月發布的長期財務展望造成任何重大影響。我們持續投資阿默達巴德,以擴充當地能力、技術與專業。我們已取得穩健進展,並將持續與 FDA 合作,確保所有未結案的觀察事項能以最快且最全面的方式解決。
In closing, we are pleased with our second quarter performance, which demonstrated the strength of our diversified portfolio. We remain squarely focused on increasing innovation and in strategically deploying capital to further accelerate our performance, always support of delivering even greater value for patients and investors.
總結而言,我們對第二季表現感到滿意,這展現了我們多元化產品組合的實力。我們仍將專注於提升創新,並以策略性方式配置資本以進一步加速表現,始終以為病患與投資人創造更大價值為目標。
I would now pass it to Jay for more details on our Q2 results and outlook for the balance of 2018.
接下來我將交給 Jay,請他就我們第二季業績以及 2018 年剩餘期間的展望提供更多細節。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Thanks, Joe, and good morning, everyone. As Joe mentioned, we're pleased with our second quarter results, which represented another solid quarter of continued momentum. I'll start by discussing our second quarter results before providing our updated financial outlook for 2018.
謝謝你,Joe,各位早安。如 Joe 所提,我們對第二季結果感到滿意,這是延續動能的又一個穩健季度。我將先說明第二季業績,接著提供我們更新後的 2018 年財務展望。
Beginning with the second quarter, global sales of $2.8 billion were in line with guidance, increasing 9% on a reported basis, 5% at constant currency and 4% on an operational basis. Key growth drivers for the quarter included increased sales of ingestible pharmaceuticals, strength in the company's renal care and acute therapy businesses as well as solid performance from our compounding and contract manufacturing businesses. And as Joe discussed, growth was partially offset by performance in our medication delivery and clinical nutrition businesses.
先從第二季開始,全球銷售額為 28 億美元,符合指引;以報告基礎計成長 9%,以固定匯率計成長 5%,以營運基礎計成長 4%。本季主要成長動能包括口服(可吞服)藥品銷售增加、公司腎臟照護與急性治療業務的強勁表現,以及我們配製與委託製造業務的穩健表現。如 Joe 所述,部分成長被藥物輸送與臨床營養業務的表現所抵銷。
On the bottom line, adjusted earnings increased 22% to $0.77 per diluted share. This exceeded our previous guidance of $0.69 to $0.71 per share, driven by solid top line performance, the ongoing benefit of our business transformation initiatives, a lower-than-expected tax rate and the other income.
在獲利方面,調整後盈餘成長 22%,至每股稀釋後 0.77 美元。此結果高於我們先前每股 0.69 至 0.71 美元的指引,主要受惠於穩健的營收表現、業務轉型計畫帶來的持續效益、低於預期的稅率以及其他收益。
Now I'll walk you through performance by our regions and Global Business Units. Note, for this quarter, constant currency sales growth is equal to operational sales growth for all businesses, with the exceptions of our pharmaceuticals and advanced surgery businesses. For these businesses, we will provide operational growth, which adjusts for the impact of generic competition for U.S. cyclophosphamide as well as the Claris and Mallinckrodt surgical product acquisitions.
接下來我將說明各區域與全球事業單位(Global Business Units)的表現。請注意,本季除製藥與先進外科業務外,所有業務的固定匯率銷售成長等同於營運銷售成長。對於這兩項業務,我們將提供營運成長數據,該數據已調整美國環磷醯胺(cyclophosphamide)學名藥競爭的影響,以及 Claris 與 Mallinckrodt 外科產品收購案的影響。
Starting first with sales growth for our 3 regions. Sales in the Americas advanced 6% on a constant currency basis and 4% operationally. Sales in Europe, Middle East and Africa grew 3%, both constant currency and operationally. And finally, sales in our Asia Pacific region rose 6% on a constant currency basis and 5% operationally.
先從三大區域的銷售成長談起。美洲地區銷售以固定匯率計成長 6%,以營運基礎計成長 4%。歐洲、中東與非洲地區銷售成長 3%,固定匯率與營運基礎皆為 3%。最後,亞太地區銷售以固定匯率計成長 6%,以營運基礎計成長 5%。
Moving on to performance by Global Business Units. Global sales for renal care were $931 million, advancing 4% on a constant currency basis. Performance was driven by solid growth in PD therapies globally as well as increased sales internationally for our HD business.
接著看各全球事業單位的表現。腎臟照護全球銷售額為 9.31 億美元,以固定匯率計成長 4%。表現主要由全球腹膜透析(PD)治療的穩健成長,以及我們血液透析(HD)業務在國際市場的銷售增加所帶動。
Sales in medication delivery were $681 million, down 2% on a constant currency basis. And as Joe discussed, growth in this business was impacted by the timing of adding new customers in the U.S. for LVPs, residuals, supply constraints for SVPs following Hurricane Maria and lower international sales resulting from reallocation of solutions volume to the U.S.
藥物輸送業務銷售額為 6.81 億美元,以固定匯率計下滑 2%。如 Joe 所述,該業務成長受到多項因素影響,包括美國大容量輸液(LVP)新增客戶導入時點、殘餘影響、瑪麗亞颶風後小容量輸液(SVP)供應受限,以及因將溶液產量重新分配至美國而導致國際銷售下降。
Pharmaceutical sales were $537 million, increasing 16% constant currency and 11% operationally. Sales growth in the quarter was driven by our injectables business, which benefited from increased sales of the BREVIBLOC due to competitive supply constraints, as well as strength in our premixed injectables and international hospital pharmacy compounding business. Sales of U.S. cyclo were $45 million in the quarter, and Claris contributed $33 million globally.
製藥業務銷售額為 5.37 億美元,以固定匯率計成長 16%,以營運基礎計成長 11%。本季銷售成長主要由我們的注射劑業務帶動;該業務受惠於競品供應受限而使 BREVIBLOC 銷售增加,同時我們的預混注射劑與國際醫院藥局配製業務亦表現強勁。本季美國 cyclo 銷售額為 4,500 萬美元,Claris 在全球貢獻 3,300 萬美元。
Moving to clinical nutrition. Total sales were $221 million, down 3% on a constant currency basis. Strong growth in international markets was offset by lower sales in the U.S., which Joe commented on earlier. Sales in advanced surgery were $204 million, increasing 12% constant currency and 2% operationally. Performance was driven by solid growth in the international markets.
接著是臨床營養。總銷售額為 2.21 億美元,以固定匯率計下滑 3%。國際市場的強勁成長被美國較低的銷售所抵銷,Joe 先前已提及。先進外科業務銷售額為 2.04 億美元,以固定匯率計成長 12%,以營運基礎計成長 2%。表現主要由國際市場的穩健成長所帶動。
As mentioned previously, we completed the acquisition of RECOTHROM and PREVELEAK earlier this year. We're pleased with the contribution of these products, which represented approximately $17 million in the quarter.
如先前所述,我們已於今年稍早完成 RECOTHROM 與 PREVELEAK 的收購。我們對這些產品的貢獻感到滿意,本季約貢獻 1,700 萬美元。
Sales in our acute therapies business were $129 million, representing growth of 10% on a constant currency basis. Growth in the quarter was driven by continued strength in global demand for Baxter's continuous renal replacement therapies.
急性治療業務銷售額為 1.29 億美元,以固定匯率計成長 10%。本季成長主要由全球對 Baxter 連續性腎臟替代治療(CRRT)的需求持續強勁所帶動。
Finally, sales in our other category, which primarily includes our contract manufacturing services, were $139 million, an increase of 20% on a constant currency basis. Performance in the quarter was primarily driven by increased demand for our contract manufacturing services.
最後,其他類別(主要包含委託製造服務)銷售額為 1.39 億美元,以固定匯率計成長 20%。本季表現主要由委託製造服務需求增加所帶動。
Moving to the rest of the P&L. Our adjusted gross margin of 45.5% increased 20 basis points over the prior year. Underlying operational expansion was partially offset by a negative impact from foreign exchange and incremental supply chain costs we absorbed during the quarter.
接著看損益表(P&L)的其餘項目。我們的調整後毛利率為 45.5%,較去年同期提高 20 個基點。核心營運擴張部分被外匯的負面影響,以及本季我們吸收的額外供應鏈成本所抵銷。
Adjusted SG&A totaled $641 million, increasing 7% on a reported basis and 4% on a constant currency basis. The positive contribution from our focus on effectively managing our expense base was offset by a lower transition service agreement income from Shire and increased freight expense as we continued to ensure adequate product availability to meet our customer needs. The acquisition of Claris added 1 point to growth in the quarter.
調整後銷售、一般及行政費用(SG&A)合計 6.41 億美元,以報告基礎計增加 7%,以固定匯率計增加 4%。我們專注於有效管理費用基礎所帶來的正面貢獻,被 Shire 的過渡服務協議(TSA)收入降低,以及為確保充足產品供應以滿足客戶需求而增加的運費所抵銷。Claris 的收購使本季成長增加 1 個百分點。
Adjusted R&D spending in the quarter of $164 million increased 6% on a reported basis and 1% on a constant currency basis versus the prior year period. Adjusted operating margin in the quarter was 17.1%, an increase of 70 basis points versus the prior year. Strong operational expansion of over 150 basis points in the quarter was also partially offset by the loss of transition service agreement income and foreign exchange.
本季調整後研發(R&D)支出為 1.64 億美元,較去年同期以報告基礎計增加 6%,以固定匯率計增加 1%。本季調整後營業利益率為 17.1%,較去年同期提高 70 個基點。本季超過 150 個基點的強勁營運擴張,也部分被過渡服務協議收入的流失與外匯因素所抵銷。
Net interest expense was $11 million in the second quarter, reflecting higher levels of interest income due to rising interest rates. Adjusted other income totaled $31 million in the quarter, primarily reflecting the benefit from the recent changes we made to our U.S. pension plan and foreign exchange gains on balance sheet positions.
第二季淨利息費用為 1,100 萬美元,反映在利率上升下利息收入水準提高。本季調整後其他收益合計 3,100 萬美元,主要反映我們近期對美國退休金計畫所做變更帶來的效益,以及資產負債表部位的外匯收益。
The adjusted tax rate was 17% for the quarter, which includes a benefit of $15 million from stock compensation. And as previously mentioned, adjusted earnings of $0.77 per diluted share exceeded our guidance of $0.69 to $0.71 per share, driven by solid top line performance, our business transformation initiatives, a lower-than-expected tax rate and other income.
本季調整後稅率為 17%,其中包含來自股票薪酬的 1,500 萬美元稅務利益。此外,如先前所提,調整後每股稀釋盈餘為 0.77 美元,優於我們每股 0.69 至 0.71 美元的指引,主要受惠於穩健的營收表現、我們的業務轉型措施、低於預期的稅率以及其他收入。
During the second quarter, we repurchased $259 million or 3.8 million shares. These repurchases were partially offset by option-related dilution in the quarter.
在第二季期間,我們回購了 2.59 億美元、約 380 萬股的股票。這些回購在本季部分被與選擇權相關的稀釋所抵銷。
Before turning to our 2018 outlook, I will briefly comment on our cash flow performance. In the first half of 2018, we generated free cash flow of $541 million, an improvement of $50 million versus the prior year, driven by underlying operational performance as well as improvements in DSO and DPO metrics.
在談到我們對 2018 年的展望之前,我將簡要評論我們的現金流表現。2018 年上半年,我們產生自由現金流 5.41 億美元,較去年同期改善 5,000 萬美元,主要由基礎營運表現,以及 DSO 與 DPO 指標的改善所帶動。
Let me conclude my comments this morning by providing our guidance for the third quarter and full year 2018. Globally, we now expect 2018 full year sales to increase approximately 6% on a reported basis, given the strengthening dollar. We continue to expect growth of approximately 5% on a constant currency basis and 4% to 5% on an operational basis. Operational base -- operational growth excludes the impact of foreign exchange, U.S. cyclophosphamide sales from the first 7 months of Claris and sales from RECOTHROM and PREVELEAK.
讓我在今天上午的最後,提供我們對 2018 年第三季與 2018 全年的指引,作為結語。在全球範圍內,考量美元走強,我們目前預期 2018 全年銷售額以報告基礎計將成長約 6%。我們仍預期以固定匯率基礎計約成長 5%,以營運基礎計成長 4% 至 5%。營運基礎——營運成長不包含外匯影響、Claris 前 7 個月的美國 cyclophosphamide 銷售,以及 RECOTHROM 與 PREVELEAK 的銷售。
Moving to guidance by business, on a constant currency and operational basis, except where otherwise noted. In renal care, we continue to expect growth of 3% to 4%. In medication delivery, we now expect sales to increase approximately 4%. We now expect our pharmaceuticals business to increase 5% to 6%, constant currency. This assumes 2018 U.S. cyclophosphamide sales of $130 million, slightly above previous guidance of $120 million. We continue to expect full year Claris sales of approximately $145 million. Adjusting for cyclo in the first 7 months of Claris, operational growth is now expected to increase approximately 5%.
接著按業務別說明指引,除非另有註明,以下均以固定匯率與營運基礎計。在腎臟照護方面,我們仍預期成長 3% 至 4%。在藥物輸送方面,我們目前預期銷售額約成長 4%。我們目前預期製藥業務以固定匯率計成長 5% 至 6%。此假設 2018 年美國 cyclophosphamide 銷售為 1.30 億美元,略高於先前 1.20 億美元的指引。我們仍預期 Claris 全年銷售約 1.45 億美元。若就 Claris 前 7 個月的 cyclo 進行調整,營運成長目前預期約提升至 5%。
Moving to clinicals and nutrition, we now expect sales growth of approximately 2%, as we work to return customers in the U.S. back to pre-hurricane purchase levels. For our advanced surgery business, we continue to expect sales to increase 8% to 9% on a constant currency basis. This includes the contribution of approximately $40 million related to the recent acquisition of RECOTHROM and PREVELEAK.
再看臨床與營養業務,我們目前預期銷售成長約 2%,因我們正努力讓美國客戶的採購量回到颶風前的水準。至於先進外科業務,我們仍預期以固定匯率計銷售成長 8% 至 9%。其中包含近期收購 RECOTHROM 與 PREVELEAK 所帶來約 4,000 萬美元的貢獻。
Excluding the impact of these sales, operational growth is expected to be between 3% and 4%. To the acute therapies business, we now anticipate growth of approximately 10%, given the strong first half performance. Finally in our other business, we now expect growth of 4% to 5%, given increased demand for our contract manufacturing services.
若排除上述銷售的影響,營運成長預期介於 3% 至 4%。在急性治療業務方面,鑑於上半年表現強勁,我們目前預期成長約 10%。最後,在其他業務方面,因合約製造服務需求增加,我們目前預期成長 4% 至 5%。
Moving down the P&L. We continue to anticipate adjusted operating margin expansion of 80 to 100 basis points. We expect net interest expense of approximately $50 million and adjusted other income of approximately $95 million for 2018.
接著往下看損益表。我們仍預期調整後營業利益率將擴張 80 至 100 個基點。我們預期 2018 年淨利息費用約 5,000 萬美元,調整後其他收入約 9,500 萬美元。
For the year, we now expect an average adjusted tax rate of approximately 17%, which reflects the lower rate we reported during the first half of the year and a continued benefit from stock compensation in the second half of the year. For full year 2018, we anticipate a diluted average share count of approximately 548 million shares, which reflects the benefit of ongoing share repurchases, offset by option-related dilution. Based on these factors, we expect 2018 adjusted earnings, excluding special items, of $2.94 to $3 per diluted share.
就全年而言,我們目前預期平均調整後稅率約為 17%,反映我們在上半年所報告的較低稅率,以及下半年持續來自股票薪酬的利益。就 2018 全年而言,我們預期稀釋後平均流通股數約 5.48 億股,反映持續股票回購帶來的效益,但被與選擇權相關的稀釋所抵銷。基於上述因素,我們預期 2018 年調整後盈餘(不含特殊項目)為每股稀釋後 2.94 至 3.00 美元。
Finally, for the year, we now expect to generate operating cash flow of approximately $2.25 billion, capital expenditures of approximately $700 million and free cash flow of approximately $1.55 billion. Specific to the third quarter of 2018, we expect sales growth of approximately 3% on a reported basis and between 3% and 4% on both constant currency and operational basis. And we expect adjusted earnings, excluding special items, of $0.72 to $0.74 per diluted share in the third quarter.
最後,就全年而言,我們目前預期營運現金流約 22.5 億美元,資本支出約 7.00 億美元,自由現金流約 15.5 億美元。針對 2018 年第三季,我們預期以報告基礎計銷售成長約 3%,以固定匯率與營運基礎計則介於 3% 至 4%。我們也預期第三季調整後盈餘(不含特殊項目)為每股稀釋後 0.72 至 0.74 美元。
With that, we can now open the call up to Q&A.
接下來,我們可以開放進入問答。
Operator
Operator
(Operator Instructions) And our first question comes from the line of Bob Hopkins of Bank of America.
(接線員指示) 我們的第一個問題來自美國銀行(Bank of America)的 Bob Hopkins。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
I just wanted to start out with a question on revenue growth in the quarter. And I think I basically heard 3 areas where things were a little slower. On the LVP side, you talked about getting new customers on the med delivery side, about tight supply on the nutritional side, about delay in sort of post-hurricane situation there. Can you just kind of quantify those 3 things and their impact on the quarter? And then talk a little bit more specifically about when you would expect those things to be fully resolved? It sounded like they'd be fully resolved by Q3 or during Q3, but I just wanted to be sure.
我想先從本季營收成長的問題開始。我認為我大致聽到有 3 個領域的進展稍微慢一些。在 LVP 方面,你們談到在藥物輸送端導入新客戶、在營養端供應偏緊,以及那邊某種程度上與颶風後情況相關的延遲。你能否大致量化這 3 件事及其對本季的影響?然後再更具體談談你們預期何時這些問題會完全解決?聽起來像是到第三季或在第三季期間就會完全解決,但我想確認一下。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
I'm going to break this question into 3 areas, so it becomes easier for us to speak about. LVP is the large volume parenterals. We have categorically not lost 1 point of share or 1 customer. We just were slower to convert new beds. We are converting new beds, as a matter of fact, we converted a significant amount of beds but late in the quarter, did not feel the effect. We also had just taken a large OEM customer from the -- from a competitor, and we did this just now in early July, okay? So what -- we were not fast enough. Coming off the hurricane, we've got our volume repositioned. We've got a supply chain with a significant amount of flexibility, and we do have now the ability to direct our volumes, not only to the U.S. but at any place in the world that we need volume. So that, I feel very comfortable. Our team is just taking a little longer, and I feel that we were going to be able to get there in the second half. Just so you know, there was about 16% of growth in the first half of the year in LVPs. So you know. 16% growth in the first half of the year. We were slower in the second quarter, probably some bleed of the inventory and are slow -- and we were slow in picking up new customers. But categorically speaking, we have not lost 1 customer and 1 point of market share. When it comes to SVP or small volume parenteral, Bob, you might do -- mute your line. So there's a -- there is a significant amount of -- thank you, perfect. The SVPs, we are in tight supply level, recovering now quite fast. So these are Mini-Bags and Mini-Bag Pluses. Plus, these products are designed to reconstitute pharmaceutical APIs, okay? So we were now in channel. Meaning, Cardinal, Owens and Medline, people who distribute our products, now we have Mini-Bags into that channel. Mini-Bag Plus is not yet there. It's going to get there in September. Meaning is that when it gets into the channel, you get volume because some of these customers will not buy directly from us. But we have to take them off the channel because we were short supply. So we also are putting these products in more than 100% allocation. And we hope, by the end of the year, early next year, Mini-Bag Plus and Mini-Bags will be off allocation. So 1 point on allocation, LVPs are 100% out of allocation. No more allocation are up for LVPs. Let's now cover the nutrition side. The nutrition side is the part that we had the worst supply issues during the hurricane, those amino acids and other nutrients. Those are slow -- we're feeling those are slower to pick up. Those are practiced changes in hospitals. We are market leaders, and we feel that they will be probably the slowest ones to tick up on the ramp up curve. It's the smallest business that we have among them all. But we feel confident that the next 6 to 8 months, we'll be able to get back into our course. It's a slower process to recover than the SVPs and LVPs. I hope that has clarified some of the questions that you and some other colleagues may have in this area.
我會把這個問題拆成 3 個面向,這樣我們比較容易討論。LVP 指的是大容量注射劑(large volume parenterals)。我們明確地說,沒有流失任何 1 個市占點或任何 1 位客戶。我們只是把新病床的轉換速度放慢了。事實上我們正在轉換新病床,我們確實轉換了相當多的病床,但發生在季度較後段,因此沒有感受到效果。另外,我們也剛從一位競爭對手那裡拿下一個大型 OEM 客戶,而且是在 7 月初才剛完成,好嗎?所以問題在於——我們的速度不夠快。颶風過後,我們已把產量重新調整到位。我們的供應鏈具備相當大的彈性,而且現在我們也有能力把產量導向,不僅是美國,也可以導向全球任何我們需要供貨的地方。因此,這一點我非常放心。我們的團隊只是花的時間稍微久一點,我認為我們在下半年就能達成。讓你知道一下,上半年 LVP 約有 16% 的成長。所以你知道。上半年成長 16%。我們在第二季比較慢,可能有一些庫存消化的影響,而且我們在爭取新客戶方面也比較慢。但明確地說,我們沒有流失任何 1 位客戶,也沒有流失任何 1 個市占點。至於 SVP(小容量注射劑,small volume parenteral),Bob,你可以——把你的線路靜音一下。所以這裡——有相當程度的——謝謝,完美。SVP 目前供應仍偏緊,但正在相當快速地恢復。這些是 Mini-Bag 和 Mini-Bag Plus。另外,這些產品是用來復溶藥品 API(活性藥物成分)的,好嗎?所以我們現在已經進入通路。也就是說,Cardinal、Owens 和 Medline 這些分銷我們產品的通路商,現在通路裡已經有 Mini-Bag。Mini-Bag Plus 還沒有進去。它會在 9 月進入。意思是,一旦進入通路,你就會看到出貨量,因為有些客戶不會直接向我們採購。但先前因為供應短缺,我們必須把他們從通路端拉下來。所以我們也正在把這些產品的配給提高到超過 100%。我們希望在今年底、明年初,Mini-Bag Plus 和 Mini-Bag 都能解除配給。關於配給再補充 1 點:LVP 已經 100% 解除配給。LVP 不再有任何配給限制。接下來談營養品(nutrition)這一塊。營養品是我們在颶風期間供應問題最嚴重的部分,包括那些胺基酸和其他營養素。這些恢復得比較慢——我們感覺回升速度較慢。這牽涉到醫院端的臨床實務改變。我們是市場領導者,但我們認為它們可能會是爬坡曲線上回升最慢的項目。在這幾個業務中,它是我們規模最小的一塊。但我們有信心在接下來 6 到 8 個月內,能回到原本的軌道。它的復原過程比 SVP 和 LVP 都更慢。希望這已釐清你以及其他同事在這方面可能有的一些問題。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Yes, definitely. Helpful. Just curious, Jay, if there's any kind of quantification of these 3 issues. And to sort of summarize all that I just heard, it sounds like the majority of all these issues will be resolved this calendar year.
是的,當然。很有幫助。只是好奇,Jay,這 3 個問題是否有任何量化方式。而且總結我剛聽到的內容,聽起來這些問題大多會在今年曆年內解決。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Bob, this is Joe. It is correct. In terms of quantification, we prefer not to get into the number of customers and things like this. I'll just give you just a bit of reference. We will probably convert approximately 4,000 beds in the second half of the year, okay? And we did about the same number in the first half. But most of that happened in the first quarter, not the second quarter. But just gave you numbers for reference, and I will stop here.
Bob,我是 Joe。沒錯。就量化而言,我們比較不想談客戶數量之類的細節。我只提供一點參考。我們下半年大概會轉換約 4,000 張病床,好嗎?而上半年我們也做了差不多同樣的數量。但大部分發生在第一季,而不是第二季。我只是提供數字作為參考,我就先說到這裡。
Operator
Operator
Our next question comes from Vijay Kumar of Evercore ISI.
下一個問題來自 Evercore ISI 的 Vijay Kumar。
Vijay Muniyappa Kumar - MD
Vijay Muniyappa Kumar - MD
So maybe I'll start one with the -- on the guidance here. Maybe just one clarification on some considered organic operational numbers in the Q. Operational was in line with how you guys were expecting it, it's just cyclo came in a little bit better. So a difference in how we do the math, so I wanted you to clarify that. And the guidance now for the year, given that 3Q operational growth guidance, that implies a big step up in a high single for Q4 for. Can you just walk us through on what changes in Q4?
那我先從——關於這裡的財測(guidance)開始問。想先釐清一下本季一些被視為有機的營運數字。營運表現符合你們原先的預期,只是 cyclo(環磷醯胺)表現稍微好一些。所以在我們計算方式上會有差異,我想請你們釐清這點。另外,今年的財測,考量到你們給的 3Q 營運成長指引,這代表 Q4 的成長要大幅跳升到高個位數。你們能否帶我們走一遍,Q4 會有哪些變化?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes. Just to give a little context on our overall sales performance in the quarter, generally speaking, we were pleased. Our operational guidance, which excludes the impact of cyclophosphamide and it also excludes the acquisitions that we've undertaken, it was 4%. Our previous -- the guidance that we've provided was 3% to 4%. So sales came in strong. I think probably the most important aspect of Joe's commentary was the diversified nature of the portfolio that we have and the fact that we were able to offset some short-term challenges with strength elsewhere in the portfolio. Now moving to the back, on an overall annual basis, our guidance operationally is 4% to 5%. And again, there is a meaningful step up in the fourth quarter. The third quarter, we guided operationally to 3% to 4%. Now you'll recall, last year, we had a settlement with a compounding customer, which was about $20 million or 1 percentage point of growth. So that's one of the elements that takes this Q3 as a little bit more challenging for us on driving this 3% to 4% growth, which again, organically, were in line with our expectations. And then going to Q4, we do have the $70 million hurricane impact that's included in our numbers last year. So you will see fast -- the fastest growth of the year we expect to take place in the fourth quarter.
好的。先提供一些本季整體銷售表現的背景,一般而言,我們感到滿意。我們的營運指引(operational guidance)排除了環磷醯胺(cyclophosphamide)的影響,也排除了我們所進行的併購影響,為 4%。我們先前提供的指引是 3% 到 4%。所以銷售表現強勁。我認為 Joe 評論中最重要的一點,可能是我們產品組合的多元化,以及我們能以組合中其他部分的強勁表現,來抵消一些短期挑戰。接著看全年,在整體年度基礎上,我們的營運指引是 4% 到 5%。而且如你所說,第四季確實會有明顯的跳升。第三季我們給的營運指引是 3% 到 4%。你會記得,去年我們與一位代工調配(compounding)客戶達成和解,金額約 2,000 萬美元,約等於 1 個百分點的成長。因此,這是使得本季 Q3 在推動 3% 到 4% 成長上對我們而言稍微更具挑戰的因素之一;不過就有機面來看,仍符合我們的預期。再到 Q4,去年我們的數字中包含了 7,000 萬美元的颶風影響。因此我們預期,全年最快的成長會出現在第四季。
Vijay Muniyappa Kumar - MD
Vijay Muniyappa Kumar - MD
Got you. And then just one on the margins, Jay. So the guide for the year is, call it, low 17s, right? And if I go back, the long-term guidance range, so we're looking at north of 20% for 2020. So that would imply 300 basis points margin expansion between '19 and '20, right? So that's a step up in margin expansion when you're looking at '19, '20 versus '18. And maybe just talk about what would cause some optimism on the margin expansion side for '19 and '20?
了解。接著問一個關於毛利率(margins)的問題,Jay。你們今年的指引大概是 17% 出頭,對吧?如果我回頭看長期指引區間,我們看到 2020 年要高於 20%。那就意味著 2019 到 2020 年之間毛利率要擴張 300 個基點,對吧?所以相較於 2018,2019、2020 的毛利率擴張步伐會更快。你能談談是什麼因素讓你們對 2019 和 2020 年的毛利率擴張更有信心嗎?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes. I mean, look, we are extremely pleased with the margin progression of the business. And this is very much in line with the expectations that we've outlined. And this is tracking very well. You'll recall, Vijay, at the spin-off, we had a 9% or 10% margin. We outlined specific plans to take that to 17% over the course of 3 years. But we also recognize in the 2018 time frame, there would be a number of headwinds that we would experience with respect to things like cyclophosphamide, the sunsetting of transition service agreement. And so if you were to adjust for those items, the 80 to 100 basis points that we expect this year is a number that's much higher than that. I mean, so as we get some of these factors behind us, in 2019 and '20, we have a clear line of sight, plans and expectations to drive the margin consistent with what we shared, targeting to 20% to 21% by 2020. I'll remind you that when we put together the long-range plan, there is no sort of unidentified item in the plan, in the sense that every single cost program is delineated and specific, included in our numbers. So there is no unidentified go get that we have to get after. It is simply about executing the plans that we've laid out and managing against that.
是的。我的意思是,你看,我們對業務毛利率的逐步提升感到非常滿意。而且這與我們先前所闡述的預期非常一致。目前進展追蹤得非常好。你會記得,Vijay,在分拆時,我們的利潤率約為9%或10%。我們提出了具體計畫,要在3年內把它提升到17%。但我們也認知到在2018年期間,會有一些逆風因素,例如環磷醯胺(cyclophosphamide)、過渡服務協議(transition service agreement)的到期等。因此,如果你把這些項目調整掉,我們預期今年的80到100個基點提升,其實是遠高於調整後的水準。也就是說,隨著這些因素在2019年與2020年逐步消退,我們對推動利潤率有清晰的可視性、計畫與預期,並將如同我們分享的那樣,目標在2020年前達到20%到21%。我也提醒你,當我們制定長期計畫時,計畫中並不存在任何所謂未被識別的項目;也就是說,每一項成本方案都已被清楚界定且具體化,並納入我們的數字之中。所以我們不需要再去追逐任何未被識別的『額外可取得』項目。這純粹就是執行我們已經擬定的計畫,並據此進行管理。
Operator
Operator
Our next question comes from Robbie Marcus of JPMorgan.
我們的下一個問題來自摩根大通(JPMorgan)的Robbie Marcus。
Robert Justin Marcus - Analyst
Robert Justin Marcus - Analyst
I wanted to talk, maybe if you can, about the pharmaceutical business as that was one of the standouts there. Particularly, cyclophosphamide revenue's gumming up for the year and a difficult comp in the U.S. business, as there was the Transderm Scop benefit last year. So maybe talk about some of the underlying trends there and how sustainable that is.
我想談談製藥業務,如果可以的話,因為那是其中一個特別突出的部分。尤其是環磷醯胺的營收在今年出現拉抬,但美國業務的比較基期很困難,因為去年有Transderm Scop帶來的利多。所以能否談談其中一些基本趨勢,以及這樣的表現有多可持續?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Robbie, the strategy of pharmaceutical is, one, to use the strength of the company in its formulation and drug delivery technologies. And it always comes back to our ability to make products consistently like cyclo, like BREVIBLOC and other drugs that are -- the generics and the competition is coming, but people have a hard time consistently making this product. So hence, the strategy that we placed in front of you guys in the -- in our Investor Day in May. It's important that we continue to expand our pharmaceutical business in tough to make molecules, cytotoxic, oncolytics. Because despite the fact that other people have the desire to get in, they don't make it consistently. So right now, there is another competitor in cyclophosphamide in the market. In BREVIBLOC, there is one coming in the month of September. And we've planned another one coming in cyclo at the end of the year. As you can see, we continue to sell cyclophosphamide. We haven't seen the one that was approved coming to the market. I think it's just a matter of time. But we have the advantage of having a consistent production of this product. And I think our team here in the U.S. has done a wonderful job, really creating the commercial opportunities to make this business more reliant on us than other people and more resilient. As you can see this business, we have spoken about this cyclophosphamide issue 2 years, 3 years ago. And we're still making the product and making a lot of money when we sell it, and we will continue to do it as long as the competitors are not getting -- or hesitant in getting the market. But I want the folks to understand that Baxter has unique capabilities, and that's the reason why we're doubling down in pharmaceuticals. We -- now we, at this moment in time, we are planning for a second cyclo to come in -- it's a third because Sandoz is already on the market. Another 2 coming in, 1 just came in, another one at the end of the year and BREVIBLOC coming in September. Those numbers are baked into our forecast and estimates.
Robbie,製藥的策略,第一,是運用公司在配方與藥物遞送技術方面的優勢。而這最終都回到我們能夠穩定一致地生產產品的能力,例如cyclo(環磷醯胺)、BREVIBLOC以及其他藥物——即使學名藥與競爭者正在進入,但很多人很難穩定一致地製造這些產品。因此,這就是我們在5月投資人日向各位提出的策略。我們必須持續擴大我們在難製造分子、細胞毒性藥物、腫瘤用藥(oncolytics)等領域的製藥業務。因為儘管其他人有意願進入,他們仍無法穩定地生產。所以目前在環磷醯胺市場上,還有另一個競爭者。在BREVIBLOC方面,9月會有一家進入。而我們也預期年底還會有另一家在cyclo進入。如你所見,我們仍持續銷售環磷醯胺。我們尚未看到那個已獲核准的競爭者實際進入市場。我認為這只是時間問題。但我們的優勢在於能夠穩定一致地生產這項產品。而我認為我們在美國的團隊做得非常出色,真正創造了商業機會,使這項業務相較於其他人更依賴我們、也更具韌性。如你所見,關於環磷醯胺的議題,我們在2年前、3年前就談過。而我們仍在生產這個產品,且在銷售時能賺取可觀利潤;只要競爭者尚未進入市場——或對進入市場仍猶豫——我們就會持續這麼做。但我希望大家理解,Baxter具備獨特能力,這也是我們加碼投入製藥的原因。我們——在此刻——正為第二個cyclo競爭者進入做準備——其實是第三個,因為Sandoz已經在市場上。另外還有兩家要進來:一家剛進來,另一家在年底,且BREVIBLOC將在9月進入。這些數字都已納入我們的預測與估算之中。
Robert Justin Marcus - Analyst
Robert Justin Marcus - Analyst
Okay. Great. And then maybe just a quick follow up for you or maybe for Jay. At the Analyst Day, you laid out your capital allocation plans. But even just since a few months ago, you continue to generate strong free cash flow, that guidance is moving higher, your stock price continues to move higher and so do other asset prices. So maybe in that context, give us your latest thoughts on how you plan to use your capital and maybe timing or expectations around that.
好的。很好。接著可能再快速追問一下,給你或Jay。在分析師日,你們闡述了資本配置計畫。但即使只是幾個月後,你們仍持續產生強勁的自由現金流,指引也在上修,股價持續走高,其他資產價格也在上升。所以在這樣的背景下,能否分享你們最新對資本使用方式的想法,以及可能的時程或相關預期?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Thank you, Robbie. Listen, our intention is as is -- it's very easy to buy shares back and we have the cash, and we've been doing a good job at that. But our intention on working very hard is actually to deploy capital in acquisitions that will positively impact the business. And we have 3 thresholds that we have to cross when it comes to acquisitions. One is sustainable revenue growth. It has to be accretive to Baxter's growth at minimum. Stronger market position and leadership and accretive to Baxter's current margins and clear path to drive margin improvements. So -- and this is not about size, it can be a niche or it can be a large market company. We are looking at significant amount of opportunities as we speak to expand Baxter's adjacencies and even looking at other opportunities that are, at the moment, available. So we want to make sure that we deploy the capital where the returns to the market can count on Baxter to return. Our execution is starting to get really good. Even with the setback that we had on the 483 at Claris, we're executing on that business extremely well. Not only that, we not only covered a vast majority of the things that the FDA wrote us up for but also have improved significantly the operation and capacity at the plant, and you can see we're up 20% on sales that came into Baxter's acquisition. The same thing with Mallinckrodt. So we're starting to get the execution in Baxter now, with an SG&A between 21% and 22% and probably next year, going sub-21%. We will be able to integrate much better acquisitions in our systems and everything else. So we need to find a good opportunity for Baxter. We're looking forward to do it, and we have the capacity and the capability to do so.
謝謝你,Robbie。聽著,我們的意圖是——回購股票很容易,我們也有現金,而且我們在這方面做得不錯。但我們真正努力的意圖,其實是把資本投入到能對業務帶來正面影響的併購上。在併購方面,我們有三個必須跨越的門檻。第一是可持續的營收成長。至少必須對Baxter的成長具有增益(accretive)。第二是更強的市場地位與領導力,並且對Baxter目前的利潤率具有增益,同時有清晰路徑推動利潤率改善。所以——這不是關於規模;它可以是利基公司,也可以是大型市場公司。我們目前正在評估大量機會,以擴展Baxter的相鄰領域(adjacencies),也在看一些目前可得的其他機會。因此,我們希望確保把資本部署在能帶來回報的地方,讓市場可以信賴Baxter能交付回報。我們的執行力正開始變得非常好。即使在Claris的483(觀察缺失)事件上遭遇挫折,我們仍在該業務上執行得非常出色。不僅如此,我們不但已涵蓋FDA指出的大多數事項,也顯著改善了工廠的營運與產能;你可以看到,該併購帶入Baxter後的銷售成長了20%。Mallinckrodt也是同樣的情況。因此,我們現在在Baxter的執行正逐步到位,SG&A維持在21%到22%之間,且可能在明年降到21%以下。我們將能在我們的系統與其他方面,更好地整合併購案。所以我們需要為Baxter找到一個好的機會。我們期待能夠做到,而且我們具備相應的產能與能力。
Operator
Operator
Our next question comes from Larry Keusch of Raymond James.
我們的下一個問題來自Raymond James的Larry Keusch。
Lawrence Soren Keusch - MD
Lawrence Soren Keusch - MD
So maybe, Joe, just to start, if my math is correct here, it looks like the U.S. growth accelerated in the 2Q from the 1Q. So maybe just some thoughts on the U.S., how the environment feels?
所以也許,Joe,先從這裡開始,如果我算得沒錯,看起來美國的成長在第二季(2Q)相較第一季(1Q)有所加速。所以能否談談對美國市場的一些看法,目前的環境感受如何?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
The environment is not bad. I think you still have low single-digit growth but consistent growth. We see no less admissions. You always have the seasonality. And now in the mid of the summer, people will not voluntarily sometimes go through for procedures. And this is not a heavy time of the year, primarily for most of the Baxter products, which are related to the times to flu and heavy hospitalization in general. But we see the U.S. market as a healthy, healthy market. We'll continue to see consolidation on the provider side. And I think a lot of movement in the payer provider area. So -- but in terms of population being treated, it's a healthy market, and it's a good market to be part of.
整體環境不算差。我認為你們仍會有低個位數的成長,但會是持續性的成長。我們沒有看到住院收治量減少。你們一向會有季節性因素。而現在正值盛夏,有時候人們不會主動來做一些處置/手術。此外,對多數與 Baxter 產品相關的需求而言,這也不是一年中最旺的時段;這些產品主要與流感季以及整體住院率偏高的時期相關。但我們認為美國市場是一個健康、非常健康的市場。我們將持續看到供應端(醫療服務提供者端)的整併。而且我認為在支付方與提供者之間會有很多動態變化。所以——但就接受治療的人口而言,這是一個健康的市場,也是值得參與的好市場。
Lawrence Soren Keusch - MD
Lawrence Soren Keusch - MD
Okay. Perfect. And then just the other question is, clearly, new products are important for the second half of the year. I think that's embedded in your guidance that you'll start to see some revenues here. Can you just, again, give us some thoughts on the status of those new products? What are the drivers? And I would assume it would be mostly weighted towards the fourth quarter.
好的。完美。接著另一個問題是,很明顯,新產品對下半年很重要。我想你們的指引已經反映了這點,也就是你們會開始看到一些營收進來。能否再跟我們談談這些新產品目前的進度狀態?主要的驅動因素是什麼?而且我猜應該會主要集中在第四季。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Yes. Let me start with the KAGUYA launch in Japan. We are excited about that. We are -- we're slightly ahead of our plan to the point that we had, actually, to accelerate some purchase of production equipment at our partner to be able to supply the market. So it is a super exciting market, Japan, because it's a high-paying market with very, very low penetration of peritoneal dialysis. So we're starting to see some good movement there. We just launched our Spectrum V9 in the U.S. We converted 1 account and a significant prospect of accounts coming up. So this is -- our U.S. team or Scott Luce and his team in the U.S. need to execute now in the second half, bringing new customers and some conversions to the table on the V9. Evo IQ and -- is our new pump outside the U.S. The first time in, I think, 15 or 17 years since we launched a new product outside the U.S. when it comes to pumps. We were growing and not only secure our current base of products in the U.K., Australia, New Zealand and Ireland, but we also plan to gain market share there. So we have now an installed base of COLLEAGUE pumps, the name of the best, that is still being used outside the U.S. And this product was launched in partnership with a company outside the U.S. We were able to bring this product to the market with the Baxter trademark points, meaning some of the features that we have in our pump is built into this product in [18 months]. So we're excited about that as well. We have PRISMAFLEX in Japan. We're now a comprehensive player in Japan. We also have PrisMAX in Europe in Q4 and more stuff coming in 2019. So we're excited about -- this is a Baxter that we haven't seen in many years, with so many launches. Now it's on us to execute.
是的。我先從日本的 KAGUYA 上市談起。我們對此感到很興奮。我們——進度略微超前於原先計畫,甚至我們實際上必須在合作夥伴那邊加速採購部分生產設備,才能供應市場需求。所以日本是一個非常令人振奮的市場,因為它是高付費市場,但腹膜透析的滲透率非常、非常低。因此我們開始看到一些不錯的進展。我們剛在美國推出 Spectrum V9。我們已經轉換了 1 個客戶帳戶,且有相當多潛在客戶帳戶即將跟進。所以——我們美國團隊,也就是 Scott Luce 和他在美國的團隊,下半年需要開始執行,把 V9 的新客戶與一些轉換案帶上來。Evo IQ——是我們在美國以外推出的新幫浦。就幫浦而言,這是我想自我們上一次在美國以外推出新產品以來,約 15 或 17 年來的第一次。我們不僅要在英國、澳洲、紐西蘭與愛爾蘭維持並鞏固現有產品基礎,同時也計畫在那裡提升市占率。因此我們目前在美國以外仍有一個已安裝基礎的 COLLEAGUE 幫浦(這個名稱是最好的),而且仍在使用。這項產品是與一家美國以外的公司合作推出的。我們能在 [18 個月] 內把這項產品帶到市場,並納入 Baxter 的商標特點,也就是把我們幫浦的一些功能特性內建到這個產品中。所以我們對此也很興奮。我們在日本也有 PRISMAFLEX。我們現在在日本已是全方位的參與者。我們也會在第四季於歐洲推出 PrisMAX,2019 年還會有更多產品推出。所以我們對此感到興奮——這是多年來少見的 Baxter,有這麼多上市計畫。現在就看我們如何執行了。
Operator
Operator
Our next question comes from Danielle Antalffy of Leerink Partners.
下一個問題來自 Leerink Partners 的 Danielle Antalffy。
Danielle Joy Antalffy - MD, Medical Supplies and Devices
Danielle Joy Antalffy - MD, Medical Supplies and Devices
Just wanted to follow up on Robbie's question regarding potential capital deployment and M&A. There's a lot of possible assets out there and potential adjacencies where you could fill some product gaps or potentially go even bigger. And I was just hoping to get a better sense from you guys on what does make the most sense strategically as it relates to adjacencies? So some examples from the Analyst Day is you're getting back into nerve repair. Is it kind of building out specific areas like that? I mean, can you give any more color on where -- what were the priorities are as it relates to parts of the business from a BD perspective?
我想延續 Robbie 關於潛在資本配置與併購(M&A)的問題。市場上有很多可能的資產,以及一些潛在的相鄰領域(adjacencies),你們可以用來補足某些產品缺口,或甚至做得更大。我只是希望能更清楚了解,從策略角度來看,談到相鄰領域時,什麼樣的方向最合理?例如在分析師日提到的,你們要重新回到神經修復領域。是像那樣去擴建特定領域嗎?我的意思是,你們能否再多提供一些細節:從商務開發(BD)的角度來看,業務的哪些部分是優先事項?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
We are -- we have presented to you the adjacencies that makes sense to us, right? So we are strong in hospital, we're strong in home. So we have that channels, we have the key account management. But also, in terms of bringing synergies to the market, we have the capability now with one of the industry's lowest SG&A, okay? So I feel that we bring that part, and we also bring the commercial ability to grow businesses. I -- we like parts of surgery, but more so, we like hospital supplies. We also like some niche products into the doctor's office in areas that may bring some of our expertise in all the setting. So we now have some very interesting things that we're looking at, some a little different than others, but it is not a lack of desire and a lack of opportunity now, and then it boils down to value. And hopefully, we can cross that bridge because value is one of the things that we continue to be focused on despite the fact that we need to meet the 3 criteria that I just outlined before at Robbie's question.
我們——我們已經向各位呈現了對我們而言合理的相鄰領域,對吧?我們在醫院端很強,在居家端也很強。所以我們有這些通路,也有關鍵客戶管理能力。同時,就把協同效益帶到市場而言,我們現在具備能力,因為我們擁有業界最低之一的 SG&A(銷售、一般及行政費用),好嗎?所以我覺得我們能帶來這一塊,同時也帶來推動業務成長的商業化能力。我——我們喜歡外科領域的某些部分,但更偏好醫院耗材/供應品。我們也喜歡一些能進入診所端的利基產品,尤其是在那些能結合我們在各種照護場域專長的領域。所以我們現在正在看一些非常有趣的標的,有些彼此差異也比較大;但目前並不是缺乏意願或缺乏機會,最後會回到估值(value)。希望我們能跨過那道門檻,因為即使我們需要符合我剛才在回答 Robbie 問題時提到的三項標準,我們仍會持續把估值作為重點。
Danielle Joy Antalffy - MD, Medical Supplies and Devices
Danielle Joy Antalffy - MD, Medical Supplies and Devices
Okay. That's fair. And just one follow-up question on the long-range plan as it relates to sales growth guidance and the operating margin expansion. I mean, this quarter, you saw another nice step up in operational sales growth. It seems like you're heading in the right direction. I just wanted to get a feel from you on your confidence in achieving the long-range plan based on these results as this is the first quarter you've reported since updating that in May.
好的。這很合理。另外再追問一題,關於長期計畫(long-range plan)中對銷售成長指引與營業利益率擴張的部分。我的意思是,本季你們的營運銷售成長又有不錯的提升。看起來你們正朝正確方向前進。我只是想了解,基於這些結果,你們對達成長期計畫的信心如何?畢竟這是你們在 5 月更新該計畫後所公布的第一個季度。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Long-range plan, as it says, is long-range. So we still -- we remain confident in our ability to meet those numbers, first of all. For several reasons, I outlined a series of new products we're launching and our effectiveness in doing so. We also have market share leadership in many areas of care that we participate. So one quarter doesn't give you the right picture for the long-range because if you think about the mix of products that Baxter is going to have in 2023, it is going to be different than what we have today. So it's going to be focused on 100-plus molecules in pharmaceuticals. It's going to have significant presence in the ICU. It's going to be in the specialty monitoring with our pumps. So things that we don't have today. So our confidence in achieving the plan on the base business is solid. We have no questions about that. The part that we need to execute and we need to launch and I'm feeling confident because the amount of products coming onto the market is the technology and the innovation. And the third piece of it is really capital deployment, so we can get that thing done correctly and continue to augment because I'm starting to feel more confident in our ability to take really tough stuff, like Claris, and turn things around and -- as we use that asset as well as tuck-in acquisitions. But I feel comfortable with a solid confidence on our LRP.
長期計畫,顧名思義,是長期的。所以首先,我們仍然——對達成那些數字的能力保持信心。原因有幾個:我剛才提到我們將推出一系列新產品,以及我們在推進上市方面的執行成效。我們在許多所參與的照護領域也具備市占領先地位。因此,單一季度無法呈現長期的正確全貌,因為如果你想想 Baxter 在 2023 年的產品組合,它會與今天不同。它將聚焦於藥品領域 100 多種分子(molecules)。它將在 ICU(加護病房)有顯著的布局。它將透過我們的幫浦進入專科監測領域。這些都是我們今天還沒有的。所以,我們對於基礎業務達成計畫的信心很穩固。我們對此沒有疑問。我們需要執行、需要推出的那一部分——而我之所以感到有信心,是因為將進入市場的產品數量,代表著技術與創新。第三個部分其實是資本配置,確保我們能把這件事做對並持續補強;因為我開始更有信心,我們有能力把像 Claris 這種非常棘手的資產扭轉過來,並且——同時運用該資產以及一些補強型併購(tuck-in acquisitions)。但總體而言,對我們的 LRP(長期計畫),我感到踏實且有充分信心。
Operator
Operator
Our next question comes from David Lewis of Morgan Stanley.
我們的下一個問題來自摩根士丹利(Morgan Stanley)的 David Lewis。
David Ryan Lewis - MD
David Ryan Lewis - MD
Maybe just one quick one for Joe and then a follow-up financial question for Jay. Joe, just coming back to medication delivery and the comments around customer acquisition speed. Is the ability to acquire a new customer or supply those new customers, is that being impacted in any way by better supply by competitors? Or any change in pricing dynamics in the saline market?
也許先給 Joe 一個簡短的問題,然後再給 Jay 一個後續的財務問題。Joe,我想回到藥品配送以及你們對客戶獲取速度的評論。獲取新客戶或為這些新客戶供貨的能力,是否在任何方面受到競爭對手供應改善的影響?或者生理食鹽水市場的定價動態是否有任何變化?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Well, we'll start, David, from the back -- from the end of your question. No, no price dynamics. These are long-term contracts. As a matter of fact, of the 3 GPOs that are in the market today, the largest ones, we have 2 already re-signed with us, and we're going to continue to re-sign customers under them, extending the longevity of this contract. So the price -- and the price that is built in is a modest increase, just to maintain with the inflation or maintain up to a certain index. So it's not the pricing that would change the dynamics and -- at least in the next 4 to 5 years because accounts actually are 5 and some have extensions built in, they go up to 7. The availability of other competitors, I would assume that one of the competitors who had a -- which had a significant issue with capacity, will come back to the market. I don't doubt that. But the contracts are locked. So for us, right now, we're picking up beds that are available. But also importantly, is to supply what most of you don't -- probably did not recognize, there's a large OEM opportunity that is out there, and we just signed one not too long ago. That brings a significant volume into Baxter from somebody else. And when that is locked, it's locked for many years. So in everything, David, it has to do with consistency of manufacturing and distribution. And I feel absolutely comfortable with our plant in North Cove, doing a wonderful job, really a wonderful job. A plant manager came in, Jon Rushford, about a year ago and has really transformed the culture of that place. Secondly, getting the network in Latin America now to be flexible that I can ship into the U.S. if I need or I can revert back to Latin America or go to Europe if I need and vice versa. That creates a unique advantage to Baxter. Not putting any of our competitors down, but we bring a different dimension of supply stability and partnership to this market.
David,我們先從你問題的後半段——也就是最後一部分開始。沒有,沒有價格動態的變化。這些都是長期合約。事實上,目前市場上的三家 GPO(團體採購組織)中,最大的那幾家,我們已經有兩家與我們完成續約,我們也會在其框架下持續與客戶續約,延長這份合約的期限。因此價格——合約內建的價格是溫和上調,主要是為了跟上通膨或維持在某個指數範圍內。所以改變動態的不是定價——至少在未來 4 到 5 年不會,因為帳戶合約通常是 5 年,有些還包含延展條款,最長可到 7 年。至於其他競爭對手的供應可得性,我推測其中一位先前在產能上出現重大問題的競爭者,會回到市場。我不懷疑這點。但合約是鎖定的。所以對我們而言,目前我們正在承接可用的床位(需求)。但同樣重要的是,去供應你們多數人可能沒有——可能未曾注意到的:市場上存在一個很大的 OEM 機會,而我們不久前才剛簽下一個。這會把原本由其他供應商提供的相當可觀的量帶到 Baxter。而一旦鎖定,就會鎖定很多年。所以 David,所有這些都與製造與配送的一致性有關。我對我們位於 North Cove 的工廠非常有信心,他們做得非常好,真的非常好。大約一年前新上任的廠長 Jon Rushford,確實改變了那裡的文化。第二點,是讓我們在拉丁美洲的供應網路更具彈性:需要時我可以出貨到美國;或是我也可以回到拉丁美洲,或需要時轉往歐洲,反之亦然。這為 Baxter 創造了獨特優勢。不是要貶低任何競爭對手,但我們為這個市場帶來了不同層次的供應穩定性與合作夥伴關係。
David Ryan Lewis - MD
David Ryan Lewis - MD
Okay, Jay. Very clear. And then -- sorry, okay, Joe. And Jay, just a couple of dynamics here on the numbers...
好的,Jay。非常清楚。然後——抱歉,好吧,Joe。Jay,關於數字這裡有幾個動態……
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
I'm surprised that you're confused on our accents. Jay has a New York accent, and I have a Brazilian accent.
我很驚訝你會被我們的口音搞混。Jay 是紐約口音,而我是巴西口音。
David Ryan Lewis - MD
David Ryan Lewis - MD
Well, I just -- I hold you both at such high esteem. You're the same in my book. So a couple of things, Jay, just on numbers here. So number one, just -- you're seeing a benefit obviously of some customer or competitive disruption in BREVIBLOC in the OEM business. We have that as sort of 2 points in terms of growth impact this year. Kind of is that close, Jay? And when could we think about those dynamics beginning to reverse? And just a second broader question, Jay, on guidance. In the back half of the year, the 4% to 5% number, at the low end, you have to have some modest acceleration to get there, obviously, more at the higher end. Are you as confident at the higher end of the range here of 4% to 5% now as you were to begin the year? Those two.
嗯,我只是——我對你們兩位都非常敬重。在我看來你們是一樣的。所以 Jay,關於數字有幾點。第一,你們顯然在 BREVIBLOC 的 OEM 業務上,因為某些客戶或競爭對手的供應中斷而受益。我們把這視為今年成長影響大約 2 個百分點。Jay,大概接近這個數字嗎?而我們何時可以預期這些動態開始反轉?第二個更廣泛的問題,Jay,關於指引。在下半年,4% 到 5% 這個數字,在低端要達到就需要一些溫和的加速,顯然在高端需要更多。你現在對 4% 到 5% 區間高端的信心,是否和年初一樣?就這兩點。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes, certainly. On the guidance question, we are very confident in the guidance in the second half of the year. I think there's a few factors in play that sort of distort the quarters a little bit. One of which is the compounding that I referenced, one of which is the hurricane that I referenced. If you were to adjust for those items, really, the piece that starts to contribute meaningfully is -- are some of these new product launches, along with some of the customer gains that we've started to see in the medication delivery business. So I think, overall, we feel quite good about it. And it's one of these areas where our line of sight to delivering the plan is as consistent as it's been. On the BREVIBLOC item, certainly, that was a contributor in the quarter. We saw maybe $15-plus-million in terms of incremental BREVIBLOC sales above plan. We do expect this to subside as we have a competitor entering in September. So -- and there are some use cases for this particular product, which we believe will abate over time. But that's been a factor -- that was factored in the quarter.
是的,當然。關於指引的問題,我們對下半年的指引非常有信心。我認為有幾個因素在作用,讓季度表現看起來有些被扭曲。其中之一是我提到的複利效應(compounding),另一個是我提到的颶風影響。如果把這些項目調整掉,真正開始有顯著貢獻的部分是——一些新產品上市,以及我們在藥品配送業務中開始看到的一些客戶增長。所以整體而言,我們感覺相當不錯。而且在這些領域,我們對交付計畫的可視性(line of sight)一如既往地穩定。至於 BREVIBLOC,確實是本季度的貢獻因素。我們看到 BREVIBLOC 的增量銷售相較於計畫高出約 1,500 萬美元以上。我們預期隨著競爭對手在 9 月進入市場,這個效應會減弱。此外,這個特定產品的一些使用情境,我們也認為會隨時間而消退。但這一直是個因素——而且已經反映在本季度。
David Ryan Lewis - MD
David Ryan Lewis - MD
Jay, just the OEM quantification on the OEM benefit, on the revenue?
Jay,關於 OEM 的量化——OEM 帶來的營收效益?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
We don't really give specifics -- yes. In terms of OEMs -- I'm sorry. So there's 2 different pieces, right? Joe referenced this concept of OEM, which is sales of IV bags to other institutions that are not necessarily hospitals, right? We're going to stop short of quantifying that particular item because from our standpoint, we don't want to get into specific customer dynamics. As it relates to other -- our other business, which did experience solid growth in the quarter, there were a number of factors going on with respect to our, what we call, our B2B business, which is really contract manufacturing for others. We were able to generate a number of new customers, and then also we saw incremental volumes being sold to current customers. So again, a good performance for us in the quarter from the "other" business. It's something that we'll see some continued performance in that regard going forward.
我們不太提供具體數字——是的。就 OEM 而言——抱歉。所以這裡有兩個不同的部分,對吧?Joe 提到的 OEM 概念,是把 IV 袋銷售給其他機構,而不一定是醫院,對吧?我們會避免量化那一項,因為從我們的角度,我們不想進入特定客戶的動態細節。至於我們的其他業務——本季度確實有穩健成長——在我們所稱的 B2B 業務方面,也就是為他人做合約製造,有多個因素同時發生。我們能夠開發多位新客戶,同時也看到對現有客戶的增量出貨量。所以再次強調,這一季我們在「其他」業務上表現不錯。展望未來,我們也會在這方面看到一些持續的表現。
Operator
Operator
Our next question comes from Isaac Ro of Goldman Sachs.
我們的下一個問題來自高盛(Goldman Sachs)的 Isaac Ro。
Isaac Ro - VP
Isaac Ro - VP
Joe, I wanted to come back to your earlier comments on the IV solutions dynamic there. And my reason for asking is the marketplace, clearly, you guys have been able to bring back some capacity. You mentioned the long-term contracting. But I'm curious if given the supply shocks that we saw last year, the -- if the nature of some of these contracting terms have changed at all to maybe incentivize vendors to ensure capacity or supply in future crises. And to the extent, that might be an advantage you can take to the market, is that something that's helped you win business? And to the extent that you might have new competitors coming in down the road to help you maintain that share in pricing that you talked about?
Joe,我想回到你先前對 IV 溶液供需動態的評論。我之所以這麼問,是因為很明顯地,你們已經能夠恢復部分產能。你提到了長期合約。但我好奇的是,鑑於我們去年看到的供應衝擊——這些合約條款的性質是否有任何改變,例如透過激勵供應商在未來危機中確保產能或供應?如果這在市場上可能成為你們的優勢,這是否有幫助你們贏得業務?以及若未來有新的競爭者進入,是否會影響你們維持你剛才談到的市占與定價?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Isaac, it's very relevant. As a matter of fact, I don't -- I think all of our future contracts, there will be some kind of clause that has a guarantee of certain volume or more penalties if you don't provide the volume. And we like that. And now we're in a comfortable position because I think spot market sellers are very opportunistic, but they may not be able to provide for the longer-term. I think with us, on the LVPs and SVPs, we are getting to a lot of contracts that have that language. I feel very comfortable in the LVPs. The SVPs, we're going to get more comfortable towards the end of the year. And towards the mid- to late '19, we're going to have more Mini-Bag Plus capacity in different locations as well, in 2 different locations, 1 coming up this December, coming from Europe, and then 1 in the Americas. New capacity for Mini-Bag Plus that can be altered between Mini-Bag Plus and Mini-Bags. So for us, having capacity on long-term contracts assure us in a tough, tough situation that happens more often than people think, which is the flu season is already hitting places like Brazil right now, we need to have solutions. And last year, it was a good lesson, I think, for the industry and for us in terms of how to be more prepared and have contingencies in place. We've been working very hard as well with the FDA to get redundancy for emergencies and things like that. But that plays a role in the contract because having that clause in the contract makes our customers more at ease with -- in a situation of a crisis and allows us also to plan for the longer-term.
Isaac,這非常相關。事實上,我不——我認為我們所有未來的合約都會有某種條款,保證一定的供應量,或是在你未能提供該供應量時有更多罰則。而我們喜歡這樣。而且現在我們處於一個相對安心的位置,因為我認為現貨市場的賣方非常機會主義,但他們未必能夠提供較長期的供應。我認為就我們而言,在LVP與SVP方面,我們正在簽下很多包含這類措辭的合約。我對LVP非常有信心。SVP方面,我們會在年底前變得更有把握。而到了2019年年中到下半年,我們也會在不同地點擁有更多Mini-Bag Plus產能,同樣是在兩個不同地點:一個將於今年12月上線、從歐洲而來,另一個在美洲。這是Mini-Bag Plus的新產能,可在Mini-Bag Plus與Mini-Bag之間切換調整。因此,對我們來說,在長期合約中擁有產能能在艱難、非常艱難的情況下給我們保障——而這種情況發生的頻率比人們想像的更高,例如流感季已經在巴西等地開始出現,我們需要有解決方案。而去年我認為對產業以及對我們而言都是很好的教訓,讓我們知道如何更充分準備並建立應變方案。我們也一直非常努力與FDA合作,為緊急狀況等取得備援能力。但這也會在合約中扮演角色,因為合約中有那樣的條款,能讓我們的客戶在危機情境下更安心,也讓我們能做更長期的規劃。
Isaac Ro - VP
Isaac Ro - VP
That's helpful. And maybe just a follow up on Claris. If I look at your comments on the 8-K regarding time line, it looks like we have something like 6 to 12 months before we'll get the next FDA inspection. Could you maybe just walk us through the top handful of priorities that you guys need to execute upon during that window to make sure that the next inspection goes well?
這很有幫助。另外可能再追問一下Claris。如果我看你們在8-K中對時間表的評論,看起來我們在下一次FDA稽查之前大概還有6到12個月。你能否帶我們走一遍,在那段期間你們需要執行的幾個最優先事項,以確保下一次稽查能順利通過?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Well, we will not do anything much different than we've been doing in the last 12 months. We are relentless working in correcting all the observations by the FDA in things that we, as Baxter, our Baxter quality system calls for. That was different before, by the way. So we are converting their documentation systems. We have -- we've built a significant amount of the plant. We have new air handling systems. We have a bunch of different things that we've been doing in preparing the plant really to be a great plant for Baxter. It is already doing well in terms of exceeding our expectations in sales in the short term. But we have a backup plan. If we cannot get to the new molecules fast enough, we're looking for CMOs that would be able to come in and get the APIs in, so we can finish the product someplace else. So we do have backup plans for that. But I have to say that our quality team, led by Jackie Kunzler; our operations team by Scott Pleau, they are squarely focused in making sure that, that plant work with the best it can to have a successful series of inspections by the FDA. Because it's not one inspection. You have to have a series of successful inspections. So we can get into the launching phase of the acquisition, launching product phase of the acquisition.
嗯,我們不會做太多與過去12個月不同的事情。我們持續不懈地修正FDA提出的所有觀察事項,並依照我們作為Baxter、Baxter品質系統所要求的方式來做。順帶一提,以前並不是這樣。因此我們正在轉換他們的文件系統。我們——我們已經建置了相當大一部分的廠房。我們有新的空調與空氣處理系統。我們做了許多不同的工作,讓這座工廠真正準備好成為Baxter的一座優秀工廠。就短期而言,它在銷售表現上已經超出我們的預期。但我們有備援計畫。如果我們無法足夠快地導入新的分子(產品),我們正在尋找能夠介入的委託製造商(CMO),把API導入,讓我們可以在其他地方完成產品的後段製程。所以在這方面我們確實有備援方案。但我必須說,我們的品質團隊由Jackie Kunzler領導;營運團隊由Scott Pleau領導,他們都非常專注於確保該工廠以最佳狀態運作,並能成功通過FDA的一系列稽查。因為這不是一次稽查就結束。你必須通過一系列成功的稽查。如此我們才能進入併購案的上市階段,也就是產品上市的階段。
Operator
Operator
Our final question comes from the line of Joanne Wuensch of BMO Capital Markets.
我們最後一個問題來自BMO Capital Markets的Joanne Wuensch。
Joanne Karen Wuensch - MD & Research Analyst
Joanne Karen Wuensch - MD & Research Analyst
I'll keep it brief. First of all, Jay, could you quantify the impact on the P&L or the operating margins in the quarter from the recent acquisitions of Claris and also the Mallinckrodt products? And then second one is a larger picture for you, Joe, is the emerging markets. Anything new in terms of the approach there? Or how -- can you give us an update on that area?
我會簡短提問。首先,Jay,你能否量化本季因近期收購Claris以及Mallinckrodt產品,對損益表或營業利益率的影響?第二個問題是更宏觀的,Joe,關於新興市場。在那邊的策略上有沒有任何新的進展?或者——你能否就那個領域給我們一個最新進度?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Okay. Let me take the emerging markets first, and Jay will close the call, answering your question. We, right now, are looking at the emerging markets of close to 5%, our outlook for the year, with significant and good growth in China, close to 8%; Eastern Europe, over 6%; and Emerging Asia, close to 5%. I think -- don't forget, we call it emerging markets, but those are 23% of our sales okay? So they are not as emerging as one may think. I'm particularly happy with China. I think China is a place that we haven't spoken much about. We took a lot -- talked a lot about Japan, but China is a country that within our long-range plan, we will exceed $1 billion, and we feel excited about that business. So I think the Two-Invoice System in China and how some changes in regulatory in China are not concerning by our watch-outs, but I think those are the things that the industry and us will overcome. It's still a significant opportunity. It's still a great market. And I think Baxter is well positioned because it has a strong team in China. So great leadership there. As a matter of fact, we're going to be there next week, doing a Growth Summit to make sure we can get even more growth in new white space opportunities within our Chinese group. So now, Jay?
好的。我先談新興市場,然後由Jay在電話會議結尾回答你的問題。我們目前對新興市場的看法是接近5%,作為我們今年的展望;其中中國有顯著且良好的成長,接近8%;東歐超過6%;新興亞洲接近5%。我想——別忘了,我們稱之為新興市場,但它們占我們銷售額的23%,好嗎?所以它們並沒有想像中那麼「新興」。我對中國特別滿意。我認為中國是我們較少談到的地方。我們談了很多日本,但中國是在我們的長期計畫中將超過10億美元的國家,我們對那項業務感到振奮。所以我認為中國的兩票制,以及中國監管上的一些變化,並不在我們的警戒事項中造成擔憂,但我想這些都是產業與我們會克服的事情。它仍然是重大的機會。它仍然是很棒的市場。而我認為Baxter具備良好定位,因為我們在中國有一支強大的團隊。那裡有很好的領導力。事實上,我們下週會到那裡舉辦一場Growth Summit(成長高峰會),以確保我們能在中國團隊內的新白地機會中取得更多成長。那麼,Jay?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes. Great. Thanks, Joe. Overall, we're pleased with the performance, as Joe mentioned earlier, of both of the acquisition, the Claris acquisition and the Mallinckrodt. In the quarter, those 2 acquisitions contributed approximately $0.02 and maybe improved the operating margin of the company about 10 basis points, although there may be some rounding in that. It's just a small amount. But from an overall standpoint, sales moving ahead in line with our expectations. And then EPS impact, very much in line with how we thought about these transactions earlier in the year.
是的。很好。謝謝你,Joe。整體而言,正如Joe先前提到的,我們對兩項收購——Claris收購案以及Mallinckrodt——的表現感到滿意。在本季,這兩項收購合計貢獻約0.02美元,並可能使公司營業利益率提升約10個基點,雖然其中可能有一些四捨五入的影響。這只是很小的幅度。但從整體角度來看,銷售進展符合我們的預期。至於EPS影響,也非常符合我們年初對這些交易的評估。
Operator
Operator
And that concludes our question-and-answer session for today. Ladies and gentlemen, this does conclude today's conference call at Baxter International. Thank you for participating. Everybody, have a great day.
以上為我們今天的問答環節。各位女士、先生,這也結束了Baxter International今天的電話會議。感謝各位參與。各位,祝大家今天愉快。